Extensive limb swelling (ELS) has been reported after vaccination with a limited number of vaccine types. We sought to describe vaccine types involved in and the clinical characteristics of ELS cases reported to the Vaccine Adverse Event Reporting System (VAERS). A case of ELS was defined as any report of edema extending at least to the elbow or knee of a vaccinated extremity. Four hundred ninety-seven cases were identified, with some describing swelling from the shoulder to the hand or the hip to the foot. Patient age ranged from 0.1 to 91 years. The proportion of reports of ELS associated with a given vaccine, among all VAERS reports received for that vaccine, varied substantially among vaccines. Most reactions began within 1 day after vaccination and involved other signs of inflammation. Postvaccination ELS can involve both the proximal and distal segments of the extremity, affects all age groups, and occurs after vaccination with a broad range of vaccines.
low) in at least 1 vaccinated extremity. Case patients with anaphylaxis and resultant swelling outside the limb were excluded. Because we wanted to evaluate the relationship between specific vaccines and ELS, we also eliminated reports from further consideration if we could not determine which vaccine(s) had been received in the swollen limb(s) (i.e., if multiple vaccines were administered but the vaccination sites were not recorded; if vaccines were administered to both upper [or both lower] extremities, but the side on which the symptoms occurred was not clearly documented; or if no vaccine type was specified). Only vaccines administered in affected limbs were included in the analysis.
To identify potential case patients, we electronically searched reports that included Coding Symbols for a Thesaurus of Adverse Reaction Terms (COSTARTs) of "edema injection site," "edema peripheral," or both and that included words such as "entire," "whole," "thigh," "forearm," "circumference," "induration," "indurated," and "diameter." We manually reviewed all VAERS reports found with this search strategy and determined which met the case definition. Among the latter, we searched for reports that suggested positive rechallenge (i.e., ELS after subsequent doses of the same vaccine). Moreover, we identified ELS cases that were "serious" adverse events, which for regulatory purposes are defined as those reported as disabling, life-threatening, fatal, requiring hospital admission or prolonged hospital stay, resulting in a congenital anomaly, or requiring medical intervention to prevent outcomes such as these [16] .
Extent of limb swelling. We classified reactions into 3 groups. "Whole-limb swelling" referred to swelling of the entire extremity (i.e., from the hip to the foot or from the shoulder to the hand). The "more-than-proximal (MTP) limb swelling" category included cases in which the entire proximal segment of the extremity was involved (i.e., from the hip to the knee or the shoulder to the elbow) and the report described swelling in the distal segment without specifying that the swelling extended all the way to the foot or hand. Cases of "proximal limb swelling" described swelling from the hip to the knee or from the shoulder to the elbow.
Case patient characteristics. Demographic information was extracted from VAERS reports. Because the type of vaccine administered often is related to patient age (e.g., diphtheria and tetanus toxoids and acellular pertussis vaccine [DTaP] is administered to children), we classified case patients into 5 age groups: !2, 2-7, 8-17, 18-64, and у65 years of age.
Vaccines. Information about vaccines, immunization dates, numbers of doses, and injection sites was obtained from VAERS reports. For each vaccine, the proportion of ELS cases was determined by dividing the number of reports of ELS by the total number of VAERS reports received for that vaccine. Because reports of ELS in a single limb after administration of a single vaccine provide the clearest evidence of an association of a particular vaccine and ELS, we analyzed such reports separately from those involving multiple limbs and/or multiple vaccines.
Concomitant symptoms. Symptom onset time was calculated as the number of days between the vaccination date and the onset date of the reported symptoms, as recorded on the VAERS report. We reviewed the reports to determine whether other cardinal signs of inflammation-erythema, warmth, and pain-were reported. We also extracted information on concomitant signs and symptoms, such as fever, influenza-like symptoms, and agitation/crying. When available, information about resolution or outcome was assessed.
Injection-site reactions other than ELS.
To consider whether ELS might be an exaggerated form of an injection-site reaction, we compared, for each vaccine, the proportion of VAERS reports that involved ELS with the proportion that involved other injection-site reactions. Through an electronic search of VAERS, we identified reports (excluding those that met the ELS case definition) with coding terms suggesting signs or symptoms at the injection site (injection-site reaction and/ or abscess, atrophy, cyst, edema, granuloma, hemorrhage, vesicle, inflammation, mass, necrosis, or pain at injection site). Reports that contained COSTARTs and/or text terms used in the search strategy for ELS but that were ultimately found not to meet the case definition could be included in the injectionsite reaction group. The proportion of injection-site reactions (other than ELS) was determined for each vaccine by dividing the number of reports of injection-site reactions by the total number of VAERS reports received for that vaccine. Figure 1 summarizes the results of our VAERS exploration and case review. We selected 497 cases, in which 504 limbs were involved. Case patient reports typically described substantial edema in the limb(s) that had received the injection(s), with details about anatomy, time course, and concomitant symptoms. For example, "Patient received vaccine and injection burned a lot; by next day left arm red and edematous from deltoid to elbow and continued to swell down into forearm and fingers for 5 days; arm red, hot; had flu-like symptoms for 4 days."
RESULTS

Case Identification
Vaccination Sites
The majority of the reports, 418 (84.1%) of 497, involved a single vaccination in a single affected limb (figure 1). Of these case patients, 252 received only 1 vaccine, and the remaining 166 received у1 vaccine in an unaffected extremity. Seventynine case patients (15.9%) received multiple vaccines in an 
Single Affected Limb and Single Vaccine
Because reports of a single affected limb and a single vaccine provide the clearest evidence of an association of a particular vaccine with ELS, we focused on these 418 cases.
Extent of limb swelling. In most cases, extensive swelling was limited to the proximal half of the extremity (table 1) . Eighty percent of affected limbs were upper extremities, and this proportion was similar among the categories of proximal, MTP, and whole-limb swelling; involvement of the lower extremities was reported only in the 2 youngest age groups (data not shown).
Case patient characteristics. Demographic and clinical characteristics of case patients are summarized in table 1. Age ranged from 0.1 to 91 years. Of case patients !18 years old, 40.0% were female, and of those у18 years old, 75.4% were female; these findings are consistent with the sex proportions observed throughout VAERS [17] . One patient died 12 days after vaccination from unrelated, preexisting medical conditions (tuberculosis, aplastic anemia, and colitis). No other deaths or life-threatening reactions were reported. Twenty other case patients were hospitalized: 9 were admitted for a presumptive diagnosis of cellulitis (although no culture results or other definitive data were provided to confirm the diagnosis), 7 for supportive care for fever and/or influenza-like symptoms, 2 for angina pectoris, and 2 for allergic reactions other than anaphylaxis. Full recovery was reported for all 20 patients. One 52-year-old woman continued to have pain, paresthesias, and weakness 4.5 months after the injection and was evaluated for neurogenic pain. No events were reported as causing permanent disability. Four reports included a coding term of "positive rechallenge," but manual review revealed that the previous local reaction did not meet our case definition of ELS.
Concomitant symptoms. The presence of other cardinal signs of inflammation and constitutional signs and symptoms, stratified by age group, is summarized in table 1. In all age groups, ELS was noted within 1 day after vaccination in approximately three-fourths of cases.
Vaccines. Among the single limb/single vaccine cases, 23 vaccine types (table 2) were reported to have been administered in an affected limb (figure 2), the most common of which were NOTE. Data are percentage of patients, unless otherwise indicated. ANTH, anthrax vaccine; DT, diphtheria and tetanus toxoids (adsorbed pediatric); DTaP, diphtheria and tetanus toxoids and acellular pertussis vaccine (adsorbed pediatric); DTP, diphtheria and tetanus toxoids and pertussis vaccine (adsorbed pediatric); DTPH, diphtheria and tetanus toxoids, acellular pertussis vaccine, and HIB (adsorbed pediatric); FLU, influenza virus vaccine; HEPB, hepatitis B vaccine; HIB, Haemophilus influenzae type B vaccine; MMR, measles, mumps, and rubella virus vaccine (live); PPV, polyvalent pneumococcal vaccine; Td, tetanus and diphtheria toxoids (adsorbed adult); TTOX, tetanus toxoid. a For 8 patients, sex was listed as "unknown." b Erythema, warmth, or pain.
polyvalent pneumococcal vaccine (PPV), DTaP, tetanus and diphtheria toxoids (adsorbed adult; Td), diphtheria and tetanus toxoids and pertussis vaccine (adsorbed pediatric; DTP), and influenza vaccine (FLU). The frequency of vaccine types varied among age categories (table 1) . The proportion of reports of ELS for a given vaccine varied substantially among vaccines, ranging from 0.03% for varicella vaccine (live; VARCEL) to 4.2% for diphtheria and tetanus toxoids, pertussis vaccine, and Haemophilus influenzae type B vaccine (HIB) (adsorbed pediatric; DTPH). A higher proportion of ELS reports was generally associated with a higher proportion of injection-site reaction reports ( figure 3 ). Among case patients р7 years old, ELS was more likely to be reported after higher numbers of doses of DTP and DTaP than after lower numbers of doses of these vaccines. Specifically, it was more frequently reported after the fifth dose (14 [35%] of 40 reports) of DTP than the first (7 reports Td, FLU, hepatitis B vaccine (HEPB), DTPH, and anthrax vaccine (ANTH), neither ELS nor other injection-site reactions were reported more frequently with increasing dose number. However, dose numbers were missing from many of reports involving these vaccines (e.g., for vaccines for which the initial series is given in multiple doses, such as HEPB and ANTH, 4.9%-25.8% of dose numbers were missing; for vaccines that are given annually or as boosters, such as FLU and Td, 34.2%-65.8% of dose numbers were missing).
Multiple Limbs and/or Multiple Vaccines
Seventy-nine reports described ELS in multiple limbs and/or receipt of multiple vaccines; 86 affected limbs were described. Extent of limb swelling. In most cases (72 [91.1%] of 79 patients), extensive swelling was reported to occur in a single limb in which multiple vaccines had been administered: 56 cases were limited to the proximal half of a single affected extremity, 15 reports described whole-limb swelling, and 1 report described MTP swelling. Extensive swelling in 11 vaccinated extremity occurred in 7 cases (8.9%), and all of these case patients were !8 years old. Approximately one-half (46 [53.5%] of 86) of the affected limbs were upper extremities. ELS was noted within 1 day after vaccination in 70 (88.6%) of 79 cases.
Case patient characteristics. The age range for this group of patients was 0.2-79 years (38.0% of patients were !2 years old, 40.5% were 2-7 years old, none were 8-17 years old, 15.2% were 18-64 years old, and 6.3% were у65 years old). Of case patients !18 years old, 37.1% were female, and of case patients у18 years old, 88.2% were female. Five case patients were hospitalized: 2 for a reported diagnosis of cellulitis (although no culture results or other definitive data were provided to confirm the diagnosis) and 3 for supportive care or observation. Full recovery was reported for all 5 of these patients. No events were reported to have caused permanent disability.
Concomitant symptoms. At least 1 cardinal sign of inflammation other than ELS was reported for 92% of case patients, and all 3 signs were reported for 6.3% of case patients. At least 1 constitutional sign or symptom was experienced by 42% of case patients, and fever was reported for 32.9%, agitation for 17.7%, and influenza-like symptoms for 5.1%.
Vaccines. 
DISCUSSION
To our knowledge, this is the largest reported case series of ELS after vaccination, although it represents only a tiny fraction of the ∼2 billion vaccine doses distributed since 1991 [17] . Cases of ELS occurred in individuals of all ages, were not more common among individuals of either sex, and, in many cases, involved the distal limb segment. Cases reported to VAERS were associated with a wide variety of vaccines, including DTaP, DTP, Td, PPV, and ANTH, for which ELS has been reported elsewhere [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] , as well as FLU, HEPB, and others. We found substantial variation by vaccine in the proportion of reports involving ELS, which suggests that some vaccine types are more reactogenic than others. Because of the limitations of a passive surveillance system, incidence rates and relative risks cannot be calculated from VAERS data. ). ANTH, anthrax vaccine; DT, diphtheria and tetanus n p 418 toxoids (adsorbed pediatric); DTaP, diphtheria and tetanus toxoids and acellular pertussis vaccine (adsorbed pediatric); DTaPH, diphtheria and tetanus toxoids, acellular pertussis vaccine, and HIB (adsorbed pediatric); DTP, diphtheria and tetanus toxoids and pertussis vaccine (adsorbed pediatric); DTPH, diphtheria and tetanus toxoids, acellular pertussis vaccine, and HIB (adsorbed pediatric); FLU, influenza virus vaccine; HBHEPB, HIB and HEPB; HEPA, hepatitis A vaccine; HEPB, hepatitis B vaccine; HIB, Haemophilus influenzae type B vaccine; IPV, inactivated poliovirus vaccine; JEV, Japanese encephalitis virus vaccine (inactivated); LYME, Lyme disease vaccine; MMR, measles, mumps, and rubella virus vaccine (live); PNC, pneumococcal 7-valent conjugate vaccine; PPV, polyvalent pneumococcal vaccine; RAB, rabies vaccine; Td, tetanus and diphtheria toxoids (adsorbed adult); TTOX, tetanus toxoid; TYP, typhoid vaccine; VARCEL, varicella vaccine (live); YF, yellow fever vaccine.
ELS might be an exaggerated injection-site reaction. That local reactions may span a continuum from minor injectionsite reactions to ELS is biologically plausible and suggests substantial variability in individual susceptibility to this adverse event. Factors relating to injection technique could play a role, but we are unable to assess this possibility using VAERS data. Our case definition excluded many reports of other severe local reactions; by focusing on ELS cases, we sought to describe in depth the clinical characteristics and vaccine types related to this adverse event, while acknowledging that details about other severe reactions remain to be determined.
In our calculations of the proportion of ELS cases and the proportions of injection-site reactions for each vaccine, we considered only reports that involved a single vaccine and a single affected limb-the vast majority of cases. For reports concerning multiple limbs and/or multiple vaccines, it was not clear whether ELS was related to only 1 vaccine or to the interaction of multiple vaccines. Further research is needed to clarify whether the simultaneous administration of multiple immunizations, particularly into a single extremity, affects the risk of ELS. For many vaccines, we found no reports of ELS. Most of these vaccines (e.g., bacille Calmette-Guérin vaccine) are administered infrequently in the United States and appear in relatively few reports in VAERS. Even common adverse events, such as symptoms at the injection site, might not be reported.
The presence of constitutional signs and symptoms among individuals with ELS whose cases are reported to VAERS is consistent with findings published elsewhere [3] [4] [5] and, combined with the time course and the presence of inflammatory signs in addition to swelling, suggests that inflammatory mediators may have a systemic effect in susceptible individuals. Seven case patients reported extensive swelling in 11 vaccinated extremity. Research involving such individuals might elucidate the inflammatory responses or other host factors that contribute to this strong propensity to severe local reactions.
Many investigators have suggested that humoral immunity responses and prior sensitization to antigens or excipients are important factors in ELS [1, 6, 7, [18] [19] [20] , although others have questioned this idea [4, 5, 10] . Accordingly, we examined the relationship between ELS and vaccine dose number. ELS was reported more frequently after higher dose numbers of DTaP and DTP than after lower dose numbers, but we identified no consistent pattern of association between dose number and symptom development (either ELS or other injection-site reactions) for any other vaccines, possibly because many of the reports were missing dose number data. We could not confirm any cases of positive rechallenge for ELS. However, a previous episode of severe injection-site reaction could be a reason not to revaccinate an individual with a given vaccine. Because VAERS does not systematically collect longitudinal information on individuals, we cannot verify that a given person is more likely to experience ELS after a later dose of DTaP or DTP than after an earlier dose. Nonetheless, our data are consistent with other reports that ELS is more common after higher dose numbers of DTaP and DTP [1, 6, 7, 18, 19] .
The present study demonstrates that ELS after vaccination can involve not only the proximal segment of the extremity that received the vaccine but also part or all of the distal segment. The symptoms are reported after a broad range of vaccines, affect people of all ages and both sexes, may involve other inflammatory signs, and generally resolve without permanent sequelae. Clinicians should be aware that this adverse event can occur after routine immunization of individuals in all age groups. Researchers should study this entity to elucidate its pathophysiology, to identify risk factors, to determine the optimal treatment strategy, and to characterize the effect of rechallenging people with a vaccine after receipt of which they previously experienced ELS. Although underreporting is an important limitation of VAERS, the identification of only 497 cases of ELS after immunization is reassuring, because ∼2 billion vaccine doses have been distributed for administration during the 12-year period covered by our study [17] . Patients, parents, and providers are encouraged to report ELS to VAERS as part of vaccine safety surveillance (Vaccine Adverse Event Reporting System, PO Box 1100, Rockville, MD 20849-1100; phone, 1-800-822-7967; fax, 1-877-721-0366; e-mail, info@vaers.org; Web site, http://www.vaers.org/).
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